Eli Lilly and Company (LLY) Q2 FY25 earnings call

Eli Lilly delivered a robust second quarter, marked by strong revenue and EPS growth, primarily fueled by its incretin franchise. The company advanced its pipeline with positive Phase III data for orforglipron and tirzepatide, while also expanding manufacturing capacity. Despite some pricing pressures and formulary exclusions, Lilly raised its full-year financial outlook, signaling confidence in its strategic execution and future growth drivers.